pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jun 11·1 min read
save

Medicare Advantage insurers often reverse denied claims on appeal, sparking concerns over care barriers

Jun 11, 2026·read at STAT ↗RegulatoryNegative

STAT's D.C. Diagnosis newsletter reports a troubling pattern in Medicare Advantage plans where initial claim denials are frequently reversed after an appeal. The analysis highlights that most large insurers overturn these denials, suggesting a systemic barrier to care for older and disabled patients.

The investigation follows earlier reporting that showed some plans used artificial intelligence to override clinicians' judgments, leading to denied services for seriously ill individuals. The new findings raise questions about the fairness and transparency of the appeals process.

The story, available to STAT+ subscribers, underscores growing scrutiny of Medicare Advantage practices and calls for policy attention to ensure patients receive needed treatments without undue obstacles.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: A suspicious denial pattern in Medicare Advantage”

read at STAT ↗
443 words · retrieved Jun 11
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
GILEADLEADINGMonte Rosa Therapeutics, Inc.NOVARTIS
topics
Molecular Glue2

related stories

  • Jun 15STAT+: Trump’s obesity drug plan creates a temporary Medicare program that may be hard to endSTAT
  • Jun 15Covid vaccination cut risk of adverse heart events, large study findsSTAT
  • Jun 11Study highlights influence of socioeconomic status on children’s brain developmentSTAT
  • Jun 11STAT+: Novartis doubles down on molecular glue strategySTAT
  • Dec 23Fierce Biotech Layoff Tracker 2026: Novartis nixes Swiss site; TScan telegraphs 75% headcount dropFierce Biotech